Crinetics Pharmaceuticals (CRNX) News Today $37.48 +0.62 (+1.67%) Closing price 02/21/2025 03:59 PM EasternExtended Trading$37.47 -0.01 (-0.02%) As of 02/21/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 Time Period Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of "Moderate Buy" from AnalystsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) has earned an average rating of "Moderate Buy" from the thirteen ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold recommendation and twelve have given a buy recommenFebruary 22 at 2:11 AM | marketbeat.comCrinetics Pharmaceuticals to Participate in Two Upcoming March Investor ConferencesFebruary 20 at 4:05 PM | globenewswire.comCrinetics Pharmaceuticals (CRNX) Projected to Post Earnings on WednesdayCrinetics Pharmaceuticals (NASDAQ:CRNX) will be releasing earnings after the market closes on Wednesday, February 26. (Register for Conference Call at http://mmm.wallstreethorizon.com/u.asp?u=663753)February 19 at 3:54 AM | marketbeat.comTD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)February 14, 2025 | americanbankingnews.comRep. Gilbert Ray Cisneros, Jr. Purchases Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Representative Gilbert Ray Cisneros, Jr. (D-California) recently bought shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on February 11th, the Representative disclosed that they had bought between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on January 29th. TFebruary 13, 2025 | marketbeat.comCRNX stock touches 52-week low at $35.47 amid market shiftsFebruary 11, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Reaches New 1-Year Low - Time to Sell?Crinetics Pharmaceuticals (NASDAQ:CRNX) Sets New 52-Week Low - What's Next?February 11, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc.: Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 11, 2025 | finanznachrichten.deCrinetics initiated with a Buy at TD CowenFebruary 11, 2025 | markets.businessinsider.comTD Cowen initiates Crinetics stock with Buy rating, sees high potentialFebruary 11, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Now Covered by TD CowenTD Cowen began coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday. They issued a "buy" rating on the stock.February 11, 2025 | marketbeat.comabrdn plc Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)abrdn plc grew its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 22.3% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 43,389 shares of the company's stock after purchasing an additional 7February 11, 2025 | marketbeat.comCrinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 10, 2025 | globenewswire.comQ3 Earnings Estimate for CRNX Issued By Leerink PartnrsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q3 2025 earnings estimates for shares of Crinetics Pharmaceuticals in a report released on Tuesday, February 4th. Leerink Partnrs analyst J. Schwartz now anticipates that theFebruary 7, 2025 | marketbeat.comCrinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results on February 27, 2025February 6, 2025 | globenewswire.comCalamos Advisors LLC Trims Stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Calamos Advisors LLC lowered its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 65.3% during the fourth quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 14,402 shares of the company's stock after selling 27,156 sharFebruary 6, 2025 | marketbeat.comWolfe Research Initiates Coverage of Crinetics Pharmaceuticals (CRNX) with Peer Perform RecommendationFebruary 6, 2025 | msn.comCrinetics Pharmaceuticals exec sells shares worth $195,350February 6, 2025 | msn.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $195,350.00 in StockCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) insider Dana Pizzuti sold 5,000 shares of the stock in a transaction on Monday, February 3rd. The shares were sold at an average price of $39.07, for a total transaction of $195,350.00. Following the transaction, the insider now directly owns 31,748 shares in the company, valued at approximately $1,240,394.36. The trade was a 13.61 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.February 5, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (CRNX): One of January’s Biggest LosersFebruary 5, 2025 | insidermonkey.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Wolfe ResearchWolfe Research started coverage on Crinetics Pharmaceuticals in a research report on Tuesday. They set a "peer perform" rating on the stock.February 4, 2025 | marketbeat.comCrinetics initiated with a Peer Perform at Wolfe ResearchFebruary 3, 2025 | markets.businessinsider.comWolfe starts Crinetics at Peer Perform, believes hedge funds turning bearishFebruary 3, 2025 | markets.businessinsider.comJennison Associates LLC Has $138.48 Million Stock Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)Jennison Associates LLC lowered its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 3.1% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 2,708,351 shares of the company's stock after selFebruary 3, 2025 | marketbeat.comWhat Are Analysts Talking About Crinetics Pharmaceuticals (CRNX)?January 29, 2025 | insidermonkey.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Average Rating of "Buy" by BrokeragesShares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) have been assigned an average recommendation of "Buy" from the eleven ratings firms that are presently covering the company, MarketBeat Ratings reports. Eleven equities research analysts have rated the stock with a buy recommJanuary 28, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Purchased by SG Americas Securities LLCSG Americas Securities LLC raised its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) by 4,084.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownedJanuary 23, 2025 | marketbeat.comCrinetics upgraded to Buy from Hold at JefferiesJanuary 23, 2025 | markets.businessinsider.comCrinetics upgraded to buy by Jefferies, atumelnant potential citedJanuary 23, 2025 | msn.comJefferies Upgrades Crinetics Pharmaceuticals (CRNX)January 23, 2025 | msn.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Upgraded to "Buy" at Jefferies Financial GroupJefferies Financial Group raised shares of Crinetics Pharmaceuticals from a "hold" rating to a "buy" rating and set a $55.00 price target on the stock in a research report on Wednesday.January 22, 2025 | marketbeat.comBrokers Offer Predictions for CRNX FY2025 EarningsCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Free Report) - Analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Crinetics Pharmaceuticals in a report issued on Tuesday, January 21st. Cantor Fitzgerald analyst J. Schimmer expects that the company will posJanuary 22, 2025 | marketbeat.comIs Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 21, 2025 | insidermonkey.comIs Crinetics Pharmaceuticals (CRNX) Among Billionaire Joseph Edelman’s Long-Term Stock Picks?January 21, 2025 | msn.comCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Sees Large Increase in Short InterestCrinetics Pharmaceuticals, Inc. (NASDAQ:CRNX - Get Free Report) was the recipient of a large growth in short interest in December. As of December 31st, there was short interest totalling 6,920,000 shares, a growth of 10.7% from the December 15th total of 6,250,000 shares. Based on an average daily volume of 776,100 shares, the days-to-cover ratio is currently 8.9 days.January 19, 2025 | marketbeat.comCrinetics Pharmaceuticals, Inc. (CRNX): The Biotech Stock with Biggest Upside PotentialJanuary 17, 2025 | insidermonkey.comCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2% - Here's WhyCrinetics Pharmaceuticals (NASDAQ:CRNX) Stock Price Down 5.2% - Should You Sell?January 16, 2025 | marketbeat.comPiper Sandler Sticks to Its Buy Rating for Crinetics Pharmaceuticals (CRNX)January 16, 2025 | markets.businessinsider.comPromising Phase 2 Results for Atumelnant Boost Crinetics Pharmaceuticals’ Buy RatingJanuary 13, 2025 | markets.businessinsider.comOppenheimer Keeps Their Buy Rating on Crinetics Pharmaceuticals (CRNX)January 13, 2025 | markets.businessinsider.comHC Wainwright Reaffirms Buy Rating for Crinetics Pharmaceuticals (NASDAQ:CRNX)HC Wainwright reiterated a "buy" rating and set a $81.00 target price on shares of Crinetics Pharmaceuticals in a research report on Monday.January 13, 2025 | marketbeat.comStrong Buy Recommendation for Crinetics Pharmaceuticals Driven by Promising Atumelnant Phase 2 Trial ResultsJanuary 12, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals: Promising Phase 2 Results and Strong Growth Potential Lead to Buy RatingJanuary 11, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals: Promising Trial Data and Strategic Advancements Support Buy RatingJanuary 11, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals’ Atumelnant Trial Data Prompts Hold Rating Amid Efficacy and Safety ConcernsJanuary 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Receives Buy Rating on Promising Phase 2 Trial Results and Strong Financial PositionJanuary 10, 2025 | markets.businessinsider.comCrinetics Pharmaceuticals Advances Atumelnant After Successful Phase 2January 10, 2025 | markets.businessinsider.comStrong Buy Rating for Crinetics Pharmaceuticals Driven by Promising Atumelnant Data and Market PotentialJanuary 10, 2025 | markets.businessinsider.comCrinetics falls after mid-stage trial data adrenal disorder therapyJanuary 10, 2025 | msn.comCrinetics Pharmaceuticals Announces January 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)January 10, 2025 | globenewswire.com Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address CRNX Media Mentions By Week CRNX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRNX News Sentiment▼0.000.60▲Average Medical News Sentiment CRNX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRNX Articles This Week▼27▲CRNX Articles Average Week Get Crinetics Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for CRNX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Viatris News Today Moderna News Today Dr. Reddy's Laboratories News Today Vaxcyte News Today Sarepta Therapeutics News Today Qiagen News Today Ascendis Pharma A/S News Today Roivant Sciences News Today Revolution Medicines News Today Legend Biotech News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRNX) was last updated on 2/22/2025 by MarketBeat.com Staff From Our PartnersSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | Sponsored[RFK Jr CONFIRMED] Here’s why Dems are TERRIFIEDRobert F. Kennedy Jr was just confirmed as Trump’s secretary of Health and Human Services… but it was NOT easy...NewMarket Health Publishing, LLC. | SponsoredBuy this AI Stock Before Elon’s AnnouncementWith Trump back in office, xAI is primed to become the leader in generative AI, leaving competitors in the dus...InvestorPlace | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhat is this southern state hiding?The financial press had a field day this week after President Donald Trump and Department of Government Effici...Stansberry Research | SponsoredElon Takes Aim at Social SecurityElon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredNvidia’s Next Big Move Comes on Feb. 26Nvidia isn't the only company that benefits greatly from these earnings calls. That's because a handful of ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Crinetics Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Crinetics Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRNX Stock Alerts